GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ME Therapeutics Holding Inc (XCNQ:METX) » Definitions » EV-to-Revenue

ME Therapeutics Holding (XCNQ:METX) EV-to-Revenue : (As of Jun. 14, 2024)


View and export this data going back to 2023. Start your Free Trial

What is ME Therapeutics Holding EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, ME Therapeutics Holding's enterprise value is C$100.42 Mil. ME Therapeutics Holding's Revenue for the trailing twelve months (TTM) ended in Feb. 2024 was C$0.00 Mil. Therefore, ME Therapeutics Holding's EV-to-Revenue for today is .

The historical rank and industry rank for ME Therapeutics Holding's EV-to-Revenue or its related term are showing as below:

XCNQ:METX's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 8.07
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-06-14), ME Therapeutics Holding's stock price is C$4.00. ME Therapeutics Holding's Revenue per Share for the trailing twelve months (TTM) ended in Feb. 2024 was C$0.00. Therefore, ME Therapeutics Holding's PS Ratio for today is .

ME Therapeutics Holding EV-to-Revenue Historical Data

The historical data trend for ME Therapeutics Holding's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ME Therapeutics Holding EV-to-Revenue Chart

ME Therapeutics Holding Annual Data
Trend Aug22 Aug23
EV-to-Revenue
- -

ME Therapeutics Holding Quarterly Data
Aug22 Dec22 May23 Aug23 Nov23 Feb24
EV-to-Revenue Get a 7-Day Free Trial - - - - -

Competitive Comparison of ME Therapeutics Holding's EV-to-Revenue

For the Biotechnology subindustry, ME Therapeutics Holding's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ME Therapeutics Holding's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ME Therapeutics Holding's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where ME Therapeutics Holding's EV-to-Revenue falls into.


ME Therapeutics Holding EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

ME Therapeutics Holding's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=100.416/0
=

ME Therapeutics Holding's current Enterprise Value is C$100.42 Mil.
ME Therapeutics Holding's Revenue for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ME Therapeutics Holding  (XCNQ:METX) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

ME Therapeutics Holding's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=4.00/0
=

ME Therapeutics Holding's share price for today is C$4.00.
ME Therapeutics Holding's Revenue per Share for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ME Therapeutics Holding EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of ME Therapeutics Holding's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

ME Therapeutics Holding (XCNQ:METX) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ME Therapeutics Holding Inc (XCNQ:METX) » Definitions » EV-to-Revenue
Comparable Companies
Traded in Other Exchanges
Q9T:Germany
Address
177 Robson Street, Vancouver, BC, CAN, V6B 0N3
Website
https://www.metherapeutics.com
ME Therapeutics Holding Inc operates its business through ME Therapeutics. It is a preclinical-stage biotechnology company working on novel cancer-fighting drugs in the field of Immuno-Oncology (IO). It is developing preclinical data for its myeloid-targeted candidate assets using validated cancer models.

ME Therapeutics Holding (XCNQ:METX) Headlines

No Headlines